AM095 is a selective LPA1 receptor antagonist used for inhibiting LPA-induced calcium flux in human and mouse LPA1-transfected CHO cells; it also inhibits GTPγS binding to membranes of CHO cells overexpressing human or mouse LPA1 receptors and suppresses LPA-driven chemotaxis in CHO cells overexpressing mouse LPA1 as well as in human A2058 melanoma cells.